KnE Medicine | The 6th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2016) | pages: 7-11

, , , , and

1. Introduction

The incidence of spontaneous miscarriage occurs more than 80% at less than 12 weeks gestation recently.At least 1 of 6 couples who has successfully conceive is going to have a miscarriage. However 40-50% incidence of miscarriage causes are not yet known. Lately, there is a popular suggestion concerning a possible link between the incidence of miscarriage with maternal immune response to fetal antigen. Maternal immune system response against fetal antigen can occur because fetus and placenta consist of paternal antigens. Progesterone can induce tolerance of maternal immune system to the fetal paternal antigens. Progestin use during first trimester of pregnancy has widely used either by physicians or midwives. However, routine progestin use in normal pregnant women has never been investigated before. Placental growth Factor (PlGF) is a homodimer glycoprotein that is homologous to Vascular Endothelial growth Factor (VEGF) produced by throphoblastic cells. Therefore, currently PlGF commonly used as an indicator on placental development and can also being used as predictor on obstetric complications related to placental disorders such as preeclampsia and interauterine growh retardation (IUGR). This study is trying to observe the increasing of PlGF (Placental Growth Factor) Level as the measurement of the placental development after administration of dydrogesterone in the pregnancy.

2. Material and Methods

This is a double blind randomized clinical trial (Randomized Controlled Clinical Trial) held at Antenatal Care clinic (ANC) at the General Hospital dr. Zainoel Abidin (RSUZA), Banda Aceh to all pregnant women undergoing first trimester ANC in RSUZA. Study population has been divided into two groups. Group A consists of 20 women who receive only Folic acid 5 mg a day for 4 weeks time. Group B consists of 20 women who receive Dydrogesterone 2x10 mg a day and Folic acid 5 mg a day for 4 weeks. PlGF has been measured twice. First measurement was done before drug administration, while the second measurement has been done during 18 t h weeks of pregnancy. The research undergone nonprobability sampling by consecutive sampling. Data analysis is done by using bivariate analysis between supplementation didrogesteron and PlGF levels using SPSS 17. Analysis of the data for comparative analytical numerical information unpaired two groups: Group A: the results in the form of PlGF levels in pregnant subjects were given progesterone and Group B: this results in a level of PlGF in pregnant patients given a placebo. If one of these groups there were no normal distribution of data, the statistical tests performed were the Mann-Whitney. If both groups have a normal distribution of the data will lead to the identification variance between groups. If the same variance (p values at variance test > 0.05), the statistical test to be used is the unpaired t test for equal variances. When variants are not the same (p value on the test variant < 0.05), the statistical test used is the unpaired t test for unequal variance. In this study all the data so that the normal distribution of data is followed by a test using unpaired t-test because it has the same variance (p values at variance test > 0.05).

3. Result and Discussion

40 pregnant women were recruited for this study. The mean age between group A and B is 28.60 vs. 27.85, which is not statistically significant (p > 0.05). The mean number of pregnancy between group A and B is 2.35 vs. 2.15, which is not statistically significant (p > 0.05). The mean number of parity between group A and B is 1.35 vs. 1.15, which is not statistically significant (p > 0.05). The mean of gestational age between group A and B is 6.85 vs. 7.25 weeks, which is not statistically significant (p > 0.05). The mean body weight between group A and B is 58.95 and 56.85 kilogram, which is not statistically significant (p > 0.05).

The mean levels of PlGF between each groups before medication shows no significant difference 25.95 vs. 40.80 pg/mL (p = 0.091 or p> 0.05). The mean levels of PlGF in group A after receiving medication is 212.15 pg/mL, which shows an elevation of 186.20 pg / mL. The results of a paired t test for PlGF levels in group A before and after treatment shows significant difference (p = 0.000 or p < 0.05). The mean levels of PlGF in group B after receiving medication is 89.60 pg/mL, which shows an elevation of 48.8 pg/mL. The results of a paired t test for PlGF levels in group B before and after treatment shows significant difference (p = 0.000 or p < 0.05). Group A shows higher increase on PlGF level increase compared to group B after medication (186.20 vs. 48.80 pg/mL), and the difference on PlGF level after being treated between each group shows significant difference (p = 0.000 or p < 0.05).

Figure 1

Individual changes on PlGF level between each group before and after treatment.

fig-1.jpg
Table 1

Data on PlGF level increase after treatment.


Group A Group B P Value
The level of increase on PlGF level 186.20 48.80 0.000 (p< 0.05)

4. Conclusion

The administration of Dydrogesterone during first trimester of pregnancy in normal pregnant women can increase PlGF level.

References

1 

Billington W. D., The immunological problem of pregnancy: 50 Years with the hope of progress. A tribute to Peter Medawar, Journal of Reproductive Immunology, Year: 2003, Volume: 60, Issue: 1, Page: 1-11. DOI: 10.1016/S0165-0378(03)00083-4

2 

Cunningham F. G., Williams Obstetrics. 23 ed., Mc. Graw Hill, New York, p. 47-72, 2010

3 

Druckmann R., Druckmann M.-A., Progesterone and the immunology of pregnancy, Journal of Steroid Biochemistry and Molecular Biology, Year: 2005, Volume: 97, Issue: 5, Page: 389-396. DOI: 10.1016/j.jsbmb.2005.08.010

4 

Espinoza J., Romero R., Nien J. K., Gomez R., Kusanovic J. P., Gonçalves L. F., Medina L., Edwin S., Hassan S., Carstens M., Gonzalez R., Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor, American Journal of Obstetrics and Gynecology, Year: 2007, Volume: 196, Issue: 4, Page: 326-e13. DOI: 10.1016/j.ajog.2006.11.002

5 

Hunt J. S., Langat D. K., McIntire R. H., Morales P. J., The role of HLA-G in human pregnancy, Reproductive Biology and Endocrinology, Year: 2006, Volume: 4, Issue: 1, article no. S10, DOI: 10.1186/1477-7827-4-S1-S10

6 

Kelly R. W., Pregnancy maintenance and parturition: The role of prostaglandin in manipulating the immune and inflammatory response, Endocrine Reviews, Year: 1994, Volume: 15, Issue: 5, Page: 684-706. DOI: 10.1210/er.15.5.684

7 

Lash G. E., Naruse K., Innes B. A., Robson S. C., Searle R. F., Bulmer J. N., Secretion of Angiogenic Growth Factors by Villous Cytotrophoblast and Extravillous Trophoblast in Early Human Pregnancy, Placenta, Year: 2010, Volume: 31, Issue: 6, Page: 545-548. DOI: 10.1016/j.placenta.2010.02.020

8 

Lin YS., Liu CH., Prediction of early pregnancy outcomes, Int J Gynaecol Obstet. Oct, Year: 1995, Volume: 51, Issue: 1, Page: 33

9 

Mishell D. R.Jr., Shoupe D., Brenner P. F., Lacarra M., Horenstein J., Lahteenmaki P., Spitz I. M., Termination of early gestation with the anti-progestin steroid RU 486: Medium versus low dose, Contraception, Year: 1987, Volume: 35, Issue: 4, Page: 307-321. DOI: 10.1016/0010-7824(87)90068-0

10 

Norwitz E. R., Schust D. J., Fisher S. J., Implantation and the survival of early pregnancy, New England Journal of Medicine, Year: 2001, Volume: 345, Issue: 19, Page: 1400-1408. DOI: 10.1056/NEJMra000763

11 

Pearson H., Immunity's pregnant pause, Nature, Year: 2002, Volume: 420, Issue: 6913, Page: 265-266. DOI: 10.1038/420265a

12 

Qureshi N. S., Treatment options for threatened miscarriage, Maturitas, Year: 2009, Volume: 65, Issue: 1, Page: S35-S41. DOI: 10.1016/j.maturitas.2009.10.010

13 

Robinson D. P., Klein S. L., Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis, Hormones and Behavior, Year: 2012, Volume: 62, Issue: 3, Page: 263-271. DOI: 10.1016/j.yhbeh.2012.02.023

14 

Sumapraja K., Saifuddin AB., Dasar-dasar Imunologi Dalam Bidang Kebidanan, Ilmu Kebidanan Sarwono Prawirohardjo., , PT Bina Pustaka Sarwono Prawirohardjo, Year: 2010, 4Jakarta Page: 97-111.

15 

Thellin O., Coumans B., Zorzi W., Igout A., Heinen E., Tolerance to the foeto-placental 'graft': Ten ways to support a child for nine months, Current Opinion in Immunology, Year: 2000, Volume: 12, Issue: 6, Page: 731-737. DOI: 10.1016/S0952-7915(00)00170-9

16 

Ullery J. C., DeNeef J. C., Holzaepfel J. H., Dydrogesterone therapy: Clinical observations and laboratory findings in 61 patients, Obstetrics and Gynecology, Year: 1963, Volume: 22, Issue: 1, Page: 38-45.

17 

Polliotti B. M., Fry A. G., Saller D. N.Jr., Mooney R. A., Cox C., Miller R. K., Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia, Obstetrics and Gynecology, Year: 2003, Volume: 101, Issue: 6, Page: 1266-1274. DOI: 10.1016/S0029-7844(03)00338-7

18 

Schindler A. E., Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium, Maturitas, Year: 2009, Volume: 65, Issue: 1, Page: S3-S11. DOI: 10.1016/j.maturitas.2009.10.011

FULL TEXT

Statistics

  • Downloads 40
  • Views 292

Navigation



ISSN: 2519-125X